Loncastuximab
Zynlonta (loncastuximab) is an antibody pharmaceutical. Loncastuximab was first approved as Zynlonta on 2022-12-20. It has been approved in Europe to treat b-cell lymphoma and large b-cell lymphoma diffuse. It is known to target B-lymphocyte antigen CD19.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zynlonta | Biologic Licensing Application | 2024-07-12 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9359 | Injection, loncastuximab tesirine-lpyl, 0.075 mg |
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 11 | 14 | 2 | — | 2 | 26 |
| B-cell lymphoma | D016393 | — | — | 8 | 9 | 2 | — | 2 | 19 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 7 | 8 | 1 | — | 1 | 15 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 4 | 1 | — | — | 7 |
| Hodgkin disease | D006689 | — | C81 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Follicular lymphoma | D008224 | — | C82 | 4 | 5 | — | — | — | 8 |
| Mantle-cell lymphoma | D020522 | — | — | 4 | 4 | — | — | — | 6 |
| Leukemia | D007938 | — | C95 | 2 | 1 | — | — | — | 3 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | 1 | — | — | — | 3 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 1 | — | — | — | 3 |
| Recurrence | D012008 | — | — | 1 | 2 | — | — | — | 3 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | 2 | — | — | — | 2 |
| Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | 1 | 1 | — | — | — | 2 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Burkitt lymphoma | D002051 | — | C83.7 | 2 | — | — | — | — | 2 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 1 | 1 |
| Agranulocytosis | D000380 | HP_0012234 | D70 | — | — | — | — | 1 | 1 |
| Toxemia | D014115 | — | — | — | — | — | — | 1 | 1 |
| Opportunistic infections | D009894 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Loncastuximab |
| INN | loncastuximab |
| Description | Loncastuximab tesirine, sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma. It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1879918-31-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297238 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB16222 |
| UNII ID | NYM5HO7I39 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 449 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
188 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use